{"product_id":"smith-nephew-pestle-analysis","title":"Smith \u0026 Nephew PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain strategic clarity with our targeted PESTLE Analysis of Smith \u0026amp; Nephew—uncover how political shifts, economic pressures, social trends, technological advances, legal changes, and environmental factors will shape growth and risk. Ideal for investors and strategists who need concise, actionable intelligence. Purchase the full report for a complete, editable breakdown you can use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating in over 100 countries, Smith \u0026amp; Nephew faces exposure to US-China trade tensions; in 2024 bilateral tariffs and tighter export controls on medical technologies risk supply-chain disruption for its ~30 manufacturing sites and could lift COGS by several percentage points. In 2025 the company’s FY revenue of £3.7bn makes maintaining global market access vital as protectionist measures threaten price competitiveness and margin erosion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reform Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment-led healthcare reforms in the US and UK—where public spending on health reached about 19.7% of GDP in the US (2023) and NHS budget was £177.4bn in 2024—reshape procurement and reimbursement, affecting Smith \u0026amp; Nephew’s revenue mix from elective procedures. Centralized purchasing pilots and value-based procurement in the NHS and US Medicare\/Medicaid can compress margins by negotiating lower device prices. A shift toward affordable access to elective surgeries forces Smith \u0026amp; Nephew to demonstrate cost-effectiveness and outcomes to protect pricing and market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStability in Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExpansion into Latin America and Southeast Asia exposes Smith \u0026amp; Nephew to localized political instability and currency swings—EMEA \u0026amp; APAC sales made up about 38% of 2024 revenue, raising exposure to FX and policy risk. Political unrest can force hospital budget cuts or delay orthopaedic infrastructure projects, reducing device procurement; e.g., healthcare capital spending in Brazil fell 6% YoY in 2024. A diversified geographic footprint mitigates concentrated regional downturns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Procurement Regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a major supplier to state-run services like the NHS, Smith \u0026amp; Nephew faces strict public tendering rules—UK public procurement spend on medical devices was about £13.5bn in 2023, making NHS contracts highly competitive and compliance-critical for the firm.\u003c\/p\u003e\n\u003cp\u003ePolitical moves toward domestic sourcing or buy-local policies—seen in 2024 UK levies and EU procurement localization trends—can raise barriers and increase bid costs for this multinational.\u003c\/p\u003e\n\u003cp\u003eProactive policy engagement is therefore vital: Smith \u0026amp; Nephew’s government affairs and clinical-evidence teams must secure procurement pathways so its surgical-tech portfolio continues to access public healthcare budgets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2023 UK medical-device procurement ≈ £13.5bn\u003c\/li\u003e\n\u003cli\u003eIncreased localization pressures in 2024 across UK\/EU\u003c\/li\u003e\n\u003cli\u003eNeed for sustained policy engagement and clinical evidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Security Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePost-pandemic political focus on health security has increased government oversight of medical supply chains, with OECD reporting 25% of member states implementing new procurement rules by 2023; Smith \u0026amp; Nephew faces heightened regulatory scrutiny on distribution and traceability.\u003c\/p\u003e\n\u003cp\u003ePolicies mandating stockpiles of wound care and orthopaedic trauma kits—some national reserves targeting 6–12 months of supply—create lumpy demand cycles that require production smoothing or buffer inventory.\u003c\/p\u003e\n\u003cp\u003eNew national mandates for medical resource self-sufficiency (e.g., EU’s 2024 resilience measures) force Smith \u0026amp; Nephew to boost manufacturing agility, possibly reallocating CAPEX—company may need to increase domestic capacity share from current ~40% to meet local content rules.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e25% of OECD states added procurement rules by 2023\u003c\/li\u003e\n\u003cli\u003eNational stockpiles target 6–12 months of essential supplies\u003c\/li\u003e\n\u003cli\u003eEU 2024 resilience measures increase local sourcing requirements\u003c\/li\u003e\n\u003cli\u003ePotential need to raise domestic capacity from ~40%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmith \u0026amp; Nephew faces rising political headwinds: trade controls, localization \u0026amp; margin pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical risks for Smith \u0026amp; Nephew include US‑China trade controls raising COGS, protectionist buy‑local policies in UK\/EU, centralized procurement and value‑based contracting (pressuring margins), regional instability in LATAM\/APAC affecting 38% of 2024 revenue, and new resilience\/localization mandates (EU 2024) forcing higher domestic capacity and CAPEX reallocation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e£3.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMEA \u0026amp; APAC share\u003c\/td\u003e\n\u003ctd\u003e≈38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUK med‑dev procurement (2023)\u003c\/td\u003e\n\u003ctd\u003e£13.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOECD new rules by 2023\u003c\/td\u003e\n\u003ctd\u003e25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how Political, Economic, Social, Technological, Environmental, and Legal forces specifically impact Smith \u0026amp; Nephew, using current market, regulatory, and industry data to identify risks and opportunities; each section contains multiple sub-points and forward-looking insights to support scenario planning and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Smith \u0026amp; Nephew PESTLE summary formatted by category for quick reference in meetings or presentations, easily dropped into slides or planning docs to support external risk discussions and cross-team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Inflationary Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising raw material, energy and labor costs have increased Smith \u0026amp; Nephew’s input expenses, with industry metals and component costs up ~8–12% in 2024 and UK electricity prices averaging 30% above 2019 levels; despite a 12-Point Plan targeting £200–250m cumulative savings by 2026, persistent inflation risks squeezing operating margin if price rises cannot be fully passed to providers, requiring strict operational efficiency and supply-chain optimization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpwith around of revenue invoiced in us dollars but reported british pounds smith nephew faces material transactional and translational fx risk a gbp move could swing by roughly percentage points. weakness vs usd ytd through nov amplified overseas earnings while stronger pound would erode uk product competitiveness. robust hedging contracts options essential to stabilize margins against volatile major pairs.\u003e\n\u003c\/pwith\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh global policy rates—e.g., average OECD policy rate near 3.5% in 2024—raise hospitals’ cost of capital, delaying purchases of robotic platforms like CORI that can cost several hundred thousand dollars per unit.\u003c\/p\u003e\n\u003cp\u003eHigher borrowing increased Smith \u0026amp; Nephew’s FY2024 net finance cost pressure; elevated rates constrain aggressive M\u0026amp;A by raising debt-servicing costs and lowering leverage capacity.\u003c\/p\u003e\n\u003cp\u003eMarkets expecting rate stabilization by late 2025 (ECB\/ Fed guidance) would likely boost healthcare capex, with hospital investment recovery potential of mid-single-digit CAGR into 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElective Surgery Volume Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe company’s revenue is closely linked to elective procedure volumes; UK \u0026amp; US elective orthopaedic volumes fell ~15% during 2020 COVID shocks and recovered to near‑prepandemic levels by 2023, but 2024 consumer confidence dips and a potential 2025 slowdown risk could push short‑term deferrals.\u003c\/p\u003e\n\u003cp\u003eAging populations support long‑term demand—global 65+ cohort grew ~8% from 2019–2024—but recessions historically delay joint replacements, lowering near‑term sales and margins.\u003c\/p\u003e\n\u003cp\u003eMonitoring disposable income, consumer confidence indexes, and procedure scheduling rates (hospital backlog metrics) is critical for forecasting quarterly revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue sensitivity: high to elective volume shifts\u003c\/li\u003e\n\u003cli\u003eRecovery seen by 2023 but 2024–25 downside risk\u003c\/li\u003e\n\u003cli\u003eDemographics provide long‑term floor\u003c\/li\u003e\n\u003cli\u003eTrack consumer confidence \u0026amp; disposable income\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-Containment in Healthcare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic constraints on public and private insurers are tightening: OECD health spending growth slowed to 2.1% in 2024, pushing payers to scrutinize medical device pricing and seek cost savings.\u003c\/p\u003e\n\u003cp\u003ePayers now demand evidence-based outcomes and value-based pricing; 68% of US hospitals in 2024 tied device purchasing to demonstrable cost reductions and patient outcomes.\u003c\/p\u003e\n\u003cp\u003eSmith \u0026amp; Nephew must show Advanced Wound Management and Orthopaedics cut long-term hospital stays—studies indicate up to 25% shorter stays with certain advanced therapies—to justify premium pricing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInsurer scrutiny up: OECD health spending growth 2.1% (2024)\u003c\/li\u003e\n\u003cli\u003e68% of US hospitals link purchasing to cost\/outcome metrics (2024)\u003c\/li\u003e\n\u003cli\u003eUp to 25% reduction in hospital stay reported with advanced wound\/ortho therapies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost pressures cut margins but GBP tailwind and ageing demand sustain healthcare growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation (metals +8–12% in 2024) and UK electricity ~+30% vs 2019 squeeze margins despite targeted £200–250m savings to 2026; FX exposure (~40% USD revenue) made GBP weakness −7% YTD 2024 materially positive; OECD policy rates ~3.5% in 2024 raise hospital capex costs, slowing elective purchases; aging population (+8% 65+ 2019–24) supports long‑term demand while payers (OECD health spend +2.1% 2024) enforce value-based pricing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetals\/component inflation\u003c\/td\u003e\n\u003ctd\u003e+8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUK electricity vs 2019\u003c\/td\u003e\n\u003ctd\u003e+30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGBP vs USD YTD\u003c\/td\u003e\n\u003ctd\u003e−7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOECD policy rate (avg)\u003c\/td\u003e\n\u003ctd\u003e~3.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e65+ population change\u003c\/td\u003e\n\u003ctd\u003e+8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOECD health spend growth\u003c\/td\u003e\n\u003ctd\u003e+2.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eSmith \u0026amp; Nephew PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Smith \u0026amp; Nephew PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic review or reporting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751790096761,"sku":"smith-nephew-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/smith-nephew-pestle-analysis.png?v=1772234702","url":"https:\/\/growthsharematrix.com\/products\/smith-nephew-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}